Merck Recalls Cholesterol Medicine Due to Packaging Defect - - BioPharm International

ADVERTISEMENT

Merck Recalls Cholesterol Medicine Due to Packaging Defect


Merck, known as MSD outside the United States and Canada, is voluntarily recalling all lots of Liptruzet (ezetimibe and atorvastatin) 10/10 mg, 10/20 mg, 10/40 mg, and 10/80 mg tablets in the United States, including Puerto Rico, due to packaging defects, the company announced in a press release. The recall affects wholesalers but not patients or pharmacies. Stock-outs are expected, but Merck is committed to resupplying Liptruzet as soon as possible.

Merck is recalling from wholesalers all lots of Liptruzet that have been distributed since the product was introduced in May 2013. Some of the outer laminate-foil pouches may allow in air and moisture, which could potentially decrease the effectiveness or change the characteristics of the product. The likelihood of the packaging defects decreasing the effectiveness of Liptruzet on a patient’s lipid profile or negatively impacting the safety of the product is remote. The decision to recall Liptruzet was not based on any reported adverse experiences or product quality complaints.

The recall will deplete all available supply in the US. The two active ingredients remain available: Zetia (ezetimibe) is available from Merck, and atorvastatin is available as a generic from multiple manufacturers. The recall does not affect any other products manufactured by Merck.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines

Click here